查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球人乳低聚糖市场 - 2023-2030 年
市场调查报告书
商品编码
1319215

全球人乳低聚糖市场 - 2023-2030 年

Global Human Milk Oligosaccharides Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 102 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

2022 年，全球人乳低聚糖 (HMO) 市场价值为 1.965 亿美元，预计到 2030 年将实现利润丰厚的增长，达到 8.505 亿美元。在 2023-2030 年的预测期内，该市场的复合年增长率将达到 20.1%。

众所周知，HMO 可支持免疫系统、促进肠道健康并有助于认知发展。随着医疗保健专业人员和消费者的认识不断提高，各年龄段（包括婴儿、儿童和成人）对基于 HMO 的产品的需求也在不断增加。

HMO 被认为是益生元，因为它们能选择性地刺激肠道有益菌的生长。HMO 的益生特性越来越受到市场的关注，越来越多的研究聚焦于 HMO 对肠道微生物群的影响以及相关的健康益处。对肠道-大脑轴的认识以及肠道健康在整体健康中的作用进一步推动了人们对作为益生元成分的 HMO 的兴趣。

市场动态

婴儿人口增长推动人乳低聚糖 (HMO) 市场增长

全球出生率不断上升。据联合国统计，每天有 385,000 名新生儿出生。每年新生儿总数超过 1.4 亿。出生率的提高导致需要适当营养的婴儿数量增加。随着父母越来越重视婴儿的营养需求，对婴儿配方奶粉和其他婴儿营养产品（包括富含 HMO 的产品）的需求也在不断增长。

婴儿喂养方式发生了转变，特别是在母乳喂养率历来较低的地区。城市化、生活方式的改变以及越来越多的职业母亲等因素促使包括使用婴儿配方奶粉在内的替代喂养方式增多。因此，人们对配方奶粉产品的要求越来越高，要求其成分和益处与母乳接近，其中包括添加 HMO。

对 HMO 优点的认识推动人乳低聚糖 (HMO) 市场增长

HMO 是母乳中的天然成分，已被证明对婴儿健康有诸多益处。它们有助于健康肠道微生物群的发育，而肠道微生物群在消化、营养吸收和免疫系统发育中起着至关重要的作用。HMO 还能降低感染、过敏和某些疾病的风险。随着人们对这些益处的认识不断加深，家长和医疗保健专业人员积极寻找以 HMO 为基础的产品，为婴儿提供最佳营养和健康支持。

人们越来越认识到健康的肠道微生物群对整体健康的重要性。HMO 可作为益生元，有选择性地滋养肠道有益菌，如双歧杆菌。它们能促进这些有益细菌的生长，同时抑制有害病原体的生长。随着研究不断揭示肠道微生物群在包括免疫功能和认知发展在内的各方面健康中的重要作用，人们对 HMO 作为支持健康肠道微生物群的一种手段的认识和需求也在不断增长。

监管和知识产权问题可能阻碍人乳低聚糖（HMO）市场的发展

食品和膳食补充剂产品中使用的 HMO 必须遵守美国食品药品管理局 (FDA) 和欧洲食品安全局 (EFSA) 等管理机构制定的监管要求。这些法规对与基于 HMO 的产品相关的安全性、标签和健康声明等方面做出了规定。满足这些法规要求可能既复杂又耗时，需要大量的资源和专业知识。难以获得监管部门的批准可能会延误产品上市，或限制基于 HMO 的产品进入市场。

知识产权在创新和市场竞争中发挥着至关重要的作用。公司投入研发力量，以创造新颖的 HMO 组合物、生产工艺和应用。获得专利可以保护这些创新，并为公司提供独占性和竞争优势。然而，如果存在重大专利纠纷、法律挑战或专有技术使用限制，知识产权问题可能会阻碍市场增长。这会限制新企业的进入，阻碍基于 HMO 的创新产品的开发。

COVID-19 影响分析

COVID-19 分析包括 COVID 前情景、COVID 情景和 COVID 后情景，以及定价动态（包括疫情期间和疫情后的定价变化，并与 COVID 前情景进行比较）、供求光谱（由于贸易限制、封锁和后续问题而导致的供求变化）、政府倡议（政府机构为振兴市场、部门或行业而采取的倡议）和制造商战略倡议（此处将涵盖制造商为缓解 COVID 问题而采取的措施）。

目 录

第 1 章：研究方法与范围

  • 研究方法
  • 报告的研究目标和范围

第2章：定义和概述

第3章：执行摘要

  • 按产品分類的片段
  • 按类型划分
  • 按应用划分
  • 按地区划分

第四章：动态

  • 影响因素
    • 驱动因素
    • 限制因素
    • 机会
    • 影响分析

第 5 章：行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID 之前的情况
    • COVID 期间的情景
    • COVID 后的情景
  • COVID-19 期间的定价动态
  • 供求关系
  • 大流行期间与市场相关的政府倡议
  • 制造商的战略倡议
  • 结论

第7章：按产品分类

  • N-新四糖乳糖（LNnT）
  • 乳糖-N-四糖（LNT）
  • 2'-Fucosyllactose (2'FL)
  • 3'-Fucosyllactose (3'FL)
  • 3'-Sialyllactose (3'SL)
  • 6'-Sialyllactose (6'SL)
  • 其他

第 8 章：按类型划分

  • 中性
  • 酸性
  • 其他

第 9 章：按应用划分

  • 婴儿配方奶粉
  • 膳食补充剂
  • 功能性食品和饮料
  • 其他

第 10 章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第 11 章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併与收购分析

第十二章 ：公司简介

  • Elicityl SA
    • 公司概况
    • 产品组合和说明
    • 财务概况
    • 主要发展
  • Medolac Laboratories
  • Inbiose NV
  • Glycosyn
  • ZuChem
  • Jennewein Biotechnologie GmbH
  • Glycom A/S
  • Dextra Laboratories Limited
  • DuPont Nutrition & Health
  • Nestle Health Science

第 13 章 ：附录

简介目录
Product Code: FB3101

Market Overview

The Global Human Milk Oligosaccharides (HMO) Market was valued US$ 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 850.5 million by 2030. The market is growing at a CAGR of 20.1% during the forecast period 2023-2030.

HMOs are known to support the immune system, promote gut health, and aid in cognitive development. As awareness spreads among healthcare professionals and consumers, there is a rising demand for HMO-based products across various age groups, including infants, children, and adults.

HMOs are considered prebiotics as they selectively stimulate the growth of beneficial gut bacteria. The prebiotic properties of HMOs are gaining attention in the market, with increased research focusing on their impact on gut microbiota and associated health benefits. The understanding of the gut-brain axis and the role of gut health in overall well-being further drive the interest in HMOs as prebiotic ingredients.

Market Dynamics

The Rising Infant Population is Driving the Market Growth of Human Milk Oligosaccharides (HMO)

The global birth rate has been increasing globally. According to the UN 385,000 newborns are born every day. That totals more than 140 million annually. This higher birth rate leads to a larger population of infants requiring proper nutrition. As parents become more conscious of the nutritional needs of their infants, there is a growing demand for infant formula and other infant nutrition products, including those enriched with HMOs.

There has been a shift in infant feeding practices, particularly in regions where breastfeeding rates have historically been low. Factors such as urbanization, changing lifestyles, and the increasing number of working mothers contribute to the rise in alternative feeding methods, including the use of infant formula. As a result, there is an increased demand for formula products that closely resemble the composition and benefits of human breast milk, which includes the incorporation of HMOs.

Awareness of HMO Benefits is Driving Human Milk Oligosaccharides (HMO) Market Growth

HMOs are natural components found in human breast milk and have been shown to provide numerous health benefits to infants. They support the development of healthy gut microbiota, which plays a crucial role in digestion, nutrient absorption, and immune system development. HMOs are also associated with reduced risks of infections, allergies, and certain diseases. As awareness of these benefits grows, parents and healthcare professionals actively seek out HMO-based products to provide optimal nutrition and support the health of infants.

There is increasing recognition of the importance of healthy gut microbiota in overall well-being. HMOs act as prebiotics, selectively nourishing beneficial gut bacteria, such as Bifidobacteria. They promote the growth of these beneficial bacteria while inhibiting the growth of harmful pathogens. As research continues to unveil the significant role of the gut microbiota in various aspects of health, including immune function and cognitive development, the awareness and demand for HMOs as a means to support healthy gut microbiota is growing.

Regulatory and Intellectual Property Issues can Hamper the Growth of the Human Milk Oligosaccharides (HMO) Market

HMOs used in food and dietary supplement products must adhere to regulatory requirements set by governing bodies, such as the U.S. Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA). These regulations govern aspects such as safety, labeling, and health claims associated with HMO-based products. Meeting these regulations can be complex and time-consuming, requiring substantial resources and expertise. Difficulties in obtaining regulatory approvals may delay product launches or limit the market entry of HMO-based products.

Intellectual property rights play a crucial role in innovation and market competition. Companies invest in research and development efforts to create novel HMO compositions, manufacturing processes, and applications. Obtaining patents protects these innovations and provides companies with exclusivity and competitive advantage. However, intellectual property issues can hamper market growth if there are significant patent disputes, legal challenges, or restrictions on the use of proprietary technologies. This can limit the entry of new players and hinder the development of innovative HMO-based products.

COVID-19 Impact Analysis

The COVID-19 Analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Segment Analysis

The global human milk oligosaccharides (HMO) market is segmented based on product, type, application, and region.

Abundance of 2'-Fucosyllactose (2'FL) in Human Milk

The global Human Milk Oligosaccharides (HMO) market has been segmented by Infant Formula, Dietary Supplements, Functional Food & Beverages, Others

In 2022, based on application, the infant formula held the highest share of the Human Milk Oligosaccharides (HMO) market.

The global demand for infant formula has been steadily increasing, driven by factors such as urbanization, changing lifestyles, and the rise in the number of working mothers. According to the Babytree/Nielsen research Infant formula makes up the great bulk of the baby care market, accounting for 72% of all sales. With more parents opting for infant formula as an alternative to breastfeeding, the demand for high-quality and nutritionally enriched formulas, including those containing HMOs, has risen significantly.

Infant formula serves as a substitute for breast milk components when breastfeeding is not possible or insufficient. HMOs are an essential component of breast milk, contributing to various health benefits for infants, including supporting the immune system, gut health, and cognitive development. The inclusion of HMOs in infant formula is aimed at providing similar benefits and promoting the growth and development of formula-fed infants.

Geographical Analysis

Growing Health Consciousness in North America Regions

In 2022, the North American region had a significant share of the Human Milk Oligosaccharides (HMO) market. North America has a well-established healthcare infrastructure and advanced research and development capabilities. The region is home to several prominent pharmaceutical and nutrition companies that are actively engaged in HMO research and product development. The strong healthcare infrastructure facilitates the production, distribution, and marketing of HMO-based products, contributing to the region's significant market share.

North America is home to several key market players in the HMO industry, including manufacturers, suppliers, and distributors. These companies have the expertise, resources, and market reach to drive the growth of HMO-based products in the region. The presence of established market players strengthens the market position of North America in the HMO industry.

Competitive Landscape

The major global players in the market include: Elicityl SA, Medolac Laboratories, Inbiose NV, Glycosyn, ZuChem, Jennewein Biotechnologie GmbH, Glycom A/S, Dextra Laboratories Limited, DuPont Nutrition & Health, Nestle Health Science

Why Purchase the Report?

  • To visualize the global human milk oligosaccharides (HMO) market segmentation based on product, type, application and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of human milk oligosaccharides (HMO) market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The Global Human Milk Oligosaccharides (HMO) Market Report Would Provide Approximately 61 Tables, 63 Figures, and 102 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Type
  • 3.3. Snippet by Application
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Lacto-N-neotetraose (LNnT) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Lacto-N-tetraose (LNT)
  • 7.4. 2'-Fucosyllactose (2'FL)
  • 7.5. 3'-Fucosyllactose (3'FL)
  • 7.6. 3'-Sialyllactose (3'SL)
  • 7.7. 6'-Sialyllactose (6'SL)
  • 7.8. Others

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Neutral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Acidic
  • 8.4. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Infant Formula*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Dietary Supplements
  • 9.4. Functional Food & Beverages
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Elicityl SA*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Medolac Laboratories
  • 12.3. Inbiose NV
  • 12.4. Glycosyn
  • 12.5. ZuChem
  • 12.6. Jennewein Biotechnologie GmbH
  • 12.7. Glycom A/S
  • 12.8. Dextra Laboratories Limited
  • 12.9. DuPont Nutrition & Health
  • 12.10. Nestle Health Science

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us